{
    "clinical_study": {
        "@rank": "63727", 
        "arm_group": {
            "arm_group_label": "Zarzio", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Purpose of the study is to investigate the safety, immunogenicity and the efficacy of Zarzio\n      under chromic administration."
        }, 
        "brief_title": "The Study on the Immunogenicity, Safety, and Efficacy of Zarzio\u00ae in Patients With Severe Chronic Neutropenia", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Chronic Neutropenia", 
        "condition_browse": {
            "mesh_term": "Neutropenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with established congenital, cyclic or idiopatc severe chronic neutropenia\n             having an indication for treatment with Zarzio\n\n        Exclusion Criteria:\n\n          -  Chemotherapy-induced neutropenia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859637", 
            "org_study_id": "EP06-401"
        }, 
        "intervention": {
            "arm_group_label": "Zarzio", 
            "intervention_name": "Eligible patients will be treated with Zarzio", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Cornelia Zeidler, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "MHH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Daniel Tesfa, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Karolinska Institut"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio\u00ae/Filgrastim HEXAL\u00ae in Patients With Severe Chronic Neutropenia", 
        "overall_contact": {
            "last_name": "Sandoz Biopharmaceuticals", 
            "phone": "+49 8024 476 0"
        }, 
        "overall_official": {
            "affiliation": "Sandoz", 
            "last_name": "Sandoz Biopharmaceuticals", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: BfArM", 
                "Sweden: MPA"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descreptive analyses", 
            "measure": "Immunogenicity: Incidences of antibodies will be determinated", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "vital signs, blood chemistry, urinanalysis", 
            "measure": "Safety: to assess the incidence of (S)AEs", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Sandoz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}